Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

This is written in the approval document as:

Pertuzumab/ trastuzumab (Phesgo) is indicated in combination with DOCEtaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.

Citation

Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab